Immobilization of an active agent on a substrate using compounds including trihydroxyphenyl groups

Patent metadata

Field	Value
Publication number	US-9655917-B2
Application number	US-201414298693-A
Country	US
Kind code	B2
Filing date	Jun 6, 2014
Priority date	Jun 7, 2013
Publication date	May 23, 2017
Grant date	May 23, 2017

Abstract

The invention provides methods of immobilizing an active agent to a substrate surface, including the steps of, providing a substrate, contacting the substrate with a solution of a compound including a trihydroxyphenyl group, thereby forming a trihydroxyphenyl-treated substrate, and contacting the trihydroxyphenyl-treated substrate with an active agent, thereby immobilizing the active agent on the substrate. Further provided are methods of immobilizing an active agent on a substrate, including the steps of providing a substrate, combining a solution of a compound including a trihydroxyphenyl group with a solution of an active agent, thereby forming a solution of an active agent-trihydroxyphenyl conjugate, and contacting the substrate with the solution of the active agent-trihydroxyphenyl conjugate, thereby immobilizing the active agent on the substrate. The invention further provides substrates and medical device or device components with active agents immobilized on the surface thereof.

First claim

What is claimed is:

1. A method of immobilizing an active agent on a substrate, comprising the steps of:
providing a substrate with a surface, the substrate surface comprising a surface of a medical device or medical device component;
contacting the substrate with a solution of a compound including a trihydroxyphenyl group thereby coupling the trihydroxyphenyl group to the substrate surface to provide a trihydroxyphenyl-treated substrate; and
contacting the trihydroxyphenyl-treated substrate with an active agent, thereby coupling the active agent to the compound including a trihydroxyphenyl group and immobilizing the active agent on the substrate, and the compound including a trihydroxyphenyl group is selected from the group consisting of gallic acid, phloroglucinol carboxylic acid, gallamide, benzenetriol, 5-methyl-benzene-1,2,3-triol, 3,4,5-trihydroxybenzaldehyde, 2,3,4-trihydroxybenzaldehyde, gallacetophenone, 3,4,5-trihydroxybenzamide, 2,3,4-trihydroxybenzoic acid, 5-hydroxydopamine hydrochloride, methyl gallate, pyrogallol, derivatives thereof, salts of the foregoing, and combinations thereof.

2. A method of immobilizing an active agent on a substrate, comprising the steps of:
providing a substrate with a surface, the substrate surface comprising a surface of a medical device or medical device component;
combining in solution a compound including a trihydroxyphenyl group and an active agent, thereby coupling the active agent to the compound including a trihydroxyphenyl group and forming a solution of an active agent-trihydroxyphenyl conjugate; and
contacting the substrate with the solution of the active agent-trihydroxyphenyl conjugate, thereby coupling the trihydroxyphenyl group of the active agent-trihydroxyphenyl conjugate to the substrate surface and immobilizing the active agent on the substrate surface, and the compound including a trihydroxyphenyl group is selected from the group consisting of gallic acid, phloroglucinol carboxylic acid, gallamide, benzenetriol, 5-methyl-benzene -1,2,3-triol, 3,4,5-trihydroxybenzaldehyde, 2,3,4-trihydroxybenzaldehyde, gallacetophenone, 3,4,5-trihydroxybenzamide, 2,3,4-trihydroxybenzoic acid, 5-hydroxydopamine hydrochloride, methyl gallate, pyrogallol, derivatives thereof, salts of the foregoing, and combinations thereof.

3. The method of claim 1 , further comprising, prior to contacting the trihydroxyphenyl-treated substrate with the active agent, the steps of rinsing the trihydroxyphenyl-treated substrate with water thereby forming a washed trihydroxyphenyl-treated substrate and optionally flowing an inert gas over the washed trihydroxyphenyl-treated substrate.

4. The method of claim 1 , wherein the compound including a trihydroxyphenyl group comprises gallic acid.

5. The method of claim 1 , further comprising activating the substrate so as to introduce a reactive moiety on the substrate surface.

6. The method of claim 1 , wherein the substrate is selected from the group consisting of metal substrates, inorganic oxide substrates, ceramic substrates, polymer substrates, semiconductor substrates and combinations thereof.

7. The method of claim 1 , wherein the medical device comprises an extracorporeal blood circuit or component of an extracorporeal blood circuit.

8. The method of claim 1 , wherein the active agent is selected from the group consisting of antimicrobial agents, antifouling agents, anti-inflammatory agents, antithrombogenic agents, and combinations thereof.

9. The method of claim 1 , wherein the active agent is selected from the group consisting of chitosan, linear polyethylene glycol, looped polyethylene glycol, polyethylene glycol derivatives, polyvinylpyrrolidone, polyvinylpyrrolidone derivatives, fractionated heparin, unfractionated heparin, heparin derivatives, quaternary ammonium polymers, albumin, polyethylenimine, 4-hydroxycoumarin derivatives, and combinations of the foregoing.

Assignees

• Baxter Int
• Baxter Healthcare Sa
• Univ Northwestern

Inventors

• Hai Ton That
• Green John-Bruce Devault
• Fulghum Timothy Michael
• Messersmith Phillip Byron
• Sileika Tadas Stanislovas

Classifications

• A61K31/722 Primary

  Chitin, chitosan · CPC title

• A61L29/085

  Macromolecular materials · CPC title

• A61K47/59

  obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes · CPC title

• A61L31/16

  Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)} · CPC title

• A61L27/34

  Macromolecular materials · CPC title